Cargando…

Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients

PURPOSE: To assess the overall survival (OS) and progression-free survival (PFS) of unresectable hepatocellular carcinoma (HCC) patients undergoing yttrium-90 glass–microsphere transarterial radioembolization (TARE) with and without concurrent sorafenib. METHODS: OS and PFS were analyzed in 55 patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teyateeti, Ajalaya, Mahvash, Armeen, Long, James P, Abdelsalam, Mohamed E, Avritscher, Rony, Chasen, Beth, Kaseb, Ahmed O, Kuban, Joshua D, Murthy, Ravi, Odisio, Bruno C, Teyateeti, Achiraya, Macapinlac, Homer A, Kappadath, S Cheenu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500841/ https://www.ncbi.nlm.nih.gov/pubmed/32984089 http://dx.doi.org/10.2147/JHC.S248314

Ejemplares similares

Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib
por: Teyateeti, Ajalaya, et al.
Publicado: (2021)

Temporary Reversal of Hepatoenteric Collaterals during (90)Y Radioembolization Planning and Administration
por: Habibollahi, Peiman, et al.
Publicado: (2022)

Temporary Balloon Occlusion of the Common Hepatic Artery for Yttrium-90 Glass Microspheres Administration in a Patient with Hepatocellular Cancer and Renal Insufficiency
por: Smith, Justin, et al.
Publicado: (2013)

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by (90)Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma
por: Kaseb, Ahmed Omar, et al.
Publicado: (2021)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
por: Mahvash, Armeen, et al.
Publicado: (2016)

Blood flow diversion using the microvascular plug to avoid non target delivery of radioactive microspheres
por: Abdelsalam, Mohamed E., et al.
Publicado: (2020)

Minimally invasive image-guided therapies for hepatocellular carcinoma
por: Abdelsalam, Mohamed E, et al.
Publicado: (2016)

Factors modulating (99m)Tc‐MAA planar lung dosimetry for (90)Y radioembolization
por: Lopez, Benjamin P., et al.
Publicado: (2022)

A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study
por: Lam, Marnix, et al.
Publicado: (2022)

Hepatic Abscess following Yttrium-90 Radioembolization in Patients with Surgical Bilioenteric Anastomosis or Compromised Sphincter of Oddi: A Tertiary Cancer Center Experience
por: Agahi, Kevin N., et al.
Publicado: (2022)

Automated segmentation of lung, liver, and liver tumors from Tc‐99m MAA SPECT/CT images for Y‐90 radioembolization using convolutional neural networks
por: Chaichana, Anucha, et al.
Publicado: (2021)

A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma
por: Zhen, Yanhua, et al.
Publicado: (2019)

Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
por: Kallini, Joseph Ralph, et al.
Publicado: (2016)

A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of (90)Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study
por: Mahvash, Armeen, et al.
Publicado: (2022)

Transarterial radioembolization with Yttrium-90: current status and future prospects
por: Yang, Hua-Yu, et al.
Publicado: (2020)

Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy
por: Hosseini Shabanan, Sedighe, et al.
Publicado: (2022)

Single-Compartment Dose Prescriptions for Ablative (90)Y-Radioembolization Segmentectomy
por: Kappadath, Srinivas Cheenu, et al.
Publicado: (2023)

Comparing voxel-based absorbed dosimetry methods in tumors, liver, lung, and at the liver-lung interface for (90)Y microsphere selective internal radiation therapy
por: Mikell, Justin K, et al.
Publicado: (2015)

Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
por: Nabrinsky, Edward, et al.
Publicado: (2020)

Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
por: Salem, Riad, et al.
Publicado: (2021)

Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model
por: Henry, E. Courtney, et al.
Publicado: (2022)

Assessment of Treatment Response Following Yttrium-90 Transarterial Radioembolization of Liver Malignancies
por: Adcock, Charles S, et al.
Publicado: (2018)

Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer
por: Puleo, Luciana, et al.
Publicado: (2022)

Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement
por: Şener, Nur, et al.
Publicado: (2023)

Reassessment of the lung dose limits for radioembolization
por: Kappadath, S. Cheenu, et al.
Publicado: (2021)

Yttrium-90 radioembolization of unresectable hepatocellular carcinoma – a single center experience
por: Meyer, Carsten, et al.
Publicado: (2017)

Correction: Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model
por: Henry, E. Courtney, et al.
Publicado: (2023)

The physics of radioembolization
por: Bastiaannet, Remco, et al.
Publicado: (2018)

Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib
por: Rana, Nitesh, et al.
Publicado: (2013)

Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review
por: Feretis, Michael, et al.
Publicado: (2020)

Direct comparison and reproducibility of two segmentation methods for multicompartment dosimetry: round robin study on radioembolization treatment planning in hepatocellular carcinoma
por: Lam, Marnix, et al.
Publicado: (2023)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Yang, Yi, et al.
Publicado: (2018)

Cost-Utility Analysis Compared Between Radiotherapy Alone and Combined Surgery and Radiotherapy for Symptomatic Spinal Metastases in Thailand
por: Taechalertpaisarn, Pasawat, et al.
Publicado: (2022)

Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma
por: Niekamp, Andrew, et al.
Publicado: (2018)

Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis
por: Al-Adra, D.P., et al.
Publicado: (2015)

Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study
por: Mosconi, Cristina, et al.
Publicado: (2016)

Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis
por: Dendy, Meaghan S., et al.
Publicado: (2017)

Transarterial Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma Patients: Outcome Assessment Applying a Prognostic Score
por: Schatka, Imke, et al.
Publicado: (2022)

Outcome comparison of patients who develop leptomeningeal disease or distant brain recurrence after brain metastases resection cavity radiosurgery
por: Teyateeti, Achiraya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ocs6u5aa93smu5gqnvrfv3iqj6